{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=10",
    "query": {
      "intervention": "Formulation #1",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 1757,
    "total_pages": 176,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T03:35:00.080Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03572062",
      "title": "A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Tract Infection"
      ],
      "interventions": [
        {
          "name": "Formulation A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Formulation B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Formulation C",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "65 Years to 85 Years"
      },
      "enrollment_count": 317,
      "start_date": "2018-06-05",
      "completion_date": "2020-08-19",
      "has_results": true,
      "last_update_posted_date": "2021-08-26",
      "last_synced_at": "2026-10-31T03:35:00.080Z",
      "location_count": 4,
      "location_summary": "South Miami, Florida • Peoria, Illinois • Fremont, Nebraska + 1 more",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Fremont",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03572062"
    },
    {
      "nct_id": "NCT01666756",
      "title": "Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Primary Hepatocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Advanced Adult Hepatocellular Carcinoma",
        "BCLC Stage B Adult Hepatocellular Carcinoma",
        "BCLC Stage C Adult Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Chinese herbal formulation PHY906",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2014-06-11",
      "completion_date": "2020-05-29",
      "has_results": false,
      "last_update_posted_date": "2021-01-27",
      "last_synced_at": "2026-10-31T03:35:00.080Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01666756"
    },
    {
      "nct_id": "NCT00834795",
      "title": "Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Carvedilol 25 mg tablets",
          "type": "DRUG"
        },
        {
          "name": "COREG® 25 mg tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2001-12",
      "completion_date": "2001-12",
      "has_results": true,
      "last_update_posted_date": "2024-08-19",
      "last_synced_at": "2026-10-31T03:35:00.080Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00834795"
    },
    {
      "nct_id": "NCT01724736",
      "title": "A Pilot Study to Determine the Effect of a Cobiotic Formulation on the Gastrointestinal Microbiome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pre Diabetic"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "NM504:",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NuMe Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 45,
      "start_date": "2012-11",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2014-07-24",
      "last_synced_at": "2026-10-31T03:35:00.080Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01724736"
    },
    {
      "nct_id": "NCT00932763",
      "title": "Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 22 Fasted, Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Amlodipine besylate",
          "type": "DRUG"
        },
        {
          "name": "Norvasc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Torrent Pharmaceuticals Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-07-17",
      "last_synced_at": "2026-10-31T03:35:00.080Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00932763"
    },
    {
      "nct_id": "NCT06958328",
      "title": "Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma",
        "Stage II Pancreatic Cancer AJCC v8",
        "Stage III Pancreatic Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Dose-escalated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Sucrosofate",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Observation Activity",
          "type": "OTHER"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Tumor Treating Fields Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 356,
      "start_date": "2025-08-21",
      "completion_date": "2030-10-21",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-31T03:35:00.080Z",
      "location_count": 332,
      "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06958328"
    },
    {
      "nct_id": "NCT00096993",
      "title": "A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 131,
      "start_date": "2005-01",
      "completion_date": "2007-09",
      "has_results": true,
      "last_update_posted_date": "2015-06-10",
      "last_synced_at": "2026-10-31T03:35:00.080Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096993"
    },
    {
      "nct_id": "NCT07136181",
      "title": "Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Uveal Melanoma",
        "Uveal Melanoma, Metastatic",
        "Uveal Melanoma, Recurrent",
        "Eye Cancer, Intraocular Melanoma",
        "Eye Cancer"
      ],
      "interventions": [
        {
          "name": "NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novelwise Pharmaceutical Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2025-11-20",
      "completion_date": "2029-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-28",
      "last_synced_at": "2026-10-31T03:35:00.080Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07136181"
    },
    {
      "nct_id": "NCT01575405",
      "title": "A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "Rectal formulation (RF) of tenofovir 1% gel",
          "type": "DRUG"
        },
        {
          "name": "Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel",
          "type": "DRUG"
        },
        {
          "name": "Universal HEC Placebo Gel Formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ian McGowan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2013-03",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2013-11-07",
      "last_synced_at": "2026-10-31T03:35:00.080Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01575405"
    },
    {
      "nct_id": "NCT03739801",
      "title": "MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Unresectable Gastric Adenocarcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Unresectable Gastric Adenocarcinoma",
        "Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Liposomal Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-04-06",
      "completion_date": "2023-04-06",
      "has_results": false,
      "last_update_posted_date": "2020-03-27",
      "last_synced_at": "2026-10-31T03:35:00.080Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03739801"
    }
  ]
}